Daunorubicin is an anti-cancer drug with considerable side-effects, including damage to the heart.

Liposomal daunorubicin, a form of the drug in which the drug is encased in fatty particles called liposomes, has been approved as first-line treatment for advanced Kaposi's sarcoma. In trials, this was just as effective as standard combination chemotherapy regimes, but caused fewer side-effects. Liposomal daunorubicin has also been tested as a treatment for lymphoma which has not responded to standard treatments, and appears to have some activity. See Non-Hodgkin's lymphoma in A to Z of illnesses for further details.

No heart toxicity has been seen to date with liposomal daunorubicin. Its main side-effect is bone marrow suppression. Another occasionally reported toxicity is the combination of back pain, flushing and chest tightness during the first ten minutes of infusion. This can be treated by slowing or halting the infusion and giving paracetamol for pain relief. Minor reactions include headache, fatigue, chills, ulceration in the mouth, lightheadedness, nausea and vomiting. No drug interactions have been seen.

Liposomal daunorubicin is administered at a dose of 40mg/m² every two weeks by intravenous infusion. It is manufactured under the tradename DaunoXome by NeXstar Pharmaceuticals Ltd.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.